H.R. 7377 — Introduced in House

I 117th CONGRESS 2d Session H. R. 7377 IN THE HOUSE OF REPRESENTATIVES April 4, 2022Mr. Curtis (for himself and Ms. Craig) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to modernize therapeutic equivalence rating determinations. 1. Short title This Act may be cited as the Modernizing Therapeutic Equivalence Rating Determination Act. 2. Therapeutic equivalence determinations Section 505(j)(7)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)(A)) is amended by adding at the end the following: (v) (I) The Secretary shall make a determination under clause (i)(III)— (aa) with respect to an application submitted under this subsection, at the time of approval of such application or not later than 30 days after the date of such approval; or (bb) with respect to an application submitted under subsection (b)(2), at the time of approval of such application or not later than 30 days after the date of such approval, provided that the sponsor requests such a determination in the original application, in a form prescribed by the Secretary. (II) When the Secretary makes a determination under clause (i)(III), the Secretary shall, in revisions made to the list pursuant to clause (ii), include such information for such drug. (III) When the Secretary makes a determination under clause (i)(III) with respect to a drug, the Secretary shall, at the same time, make such a determination with respect to any other drug— (aa) whose application under subsection (b)(2) was approved; (bb) which references the same listed drug as the application for the first drug for which such determination is made; and (cc) for which there is a citizen petition pending requesting that the Secretary make a determination under clause (i)(III). .